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Colorectal cancer accounts worldwide for about 1 million new cases per year and is the third most 
common cancer in men and the second most common in women. Although recent advances in 
treatment have improved the prognosis, CRCs remain to present 8 % of all cancers [1-3]. Research has 
shown that the most CRCs arise in colorectal polyps before developing into malignant disease. 
Therefore, resecting the adenomatous polyps by colonoscopy can help to prevent CRCs [4]. The 
incidence of CRC has been found to be associated with increasing age. CRCs can occur in young people, 
but around 90 % of CRCs are diagnosed after 40 years of age and incidences continue to increase even 
more rapidly after this age. In addition, older patients with CRC have unique treatment challenges [5]. 
Although there is a way to completely prevent CRCs taking advantage of screening methods, 
investigating the biomarkers and clinical factors of CRC that can lead to optimize diagnosis and 
treatment regimens are essential.  
 
A common feature of all cancers is the imbalance of the proliferative activity and cell death. Ki67 is 
nucleus antigen. Ki67 antibody recognized the corresponding antigen from G1 to M-phase of the cell 
proliferation, but is absent from resting cells (G0). Therefore, Ki67 is an excellent marker to determine 
the growth fraction of tumor cells, and likewise it could probably reflect clinical process [6]. Many 
studies have shown a predictive function of Ki67 in breast cancer and neuroendocrine tumors [7–9]. 
The quantification of Ki67 expression as Ki67 labeling index (Ki67-Li) was demonstrated significantly 
higher in liver metastases than primary tumor of CRC [10]. Ki67 staining of core biopsies of lymph 
node were significantly associated with poor prognosis of CRC, the nuclear staining of Ki67 
demonstrated decreased levels in rectal cancer with chemotherapy with cetuximab [11, 12, 14]. 
Higher Ki67-Li was observed as a biomarker to detect renal cell carcinoma (RCC) with high risk for 
metastases [13]. Ki67 was found to be highly expressed in the proliferative basal half of the crypt and 
was significantly elevated in ulcerative colitis (UC) colons compared to non-UC control samples [15, 
16]. In CRCs, the analysis of Ki67 has shown different patterns connected with patients’ age, 
pathological tumor differentiation, and lymph node metastasis [17-20]. However, not all studies are in 
agreement with the associations between Ki67-Li and clinicopathological information for CRCs. We set 
out to investigate whether assessment of Ki67 could also help to define the prognosis for patients 
with CRC more accurately.  
 
The notion that age can be a significant prognostic factor in CRC remains controversial. Some studies 
have shown poorer prognosis for younger patients with CRC [31-34]. Contradictory, other authors 
have demonstrated that younger patients with CRC have better prognoses compared with elderly 
ones [35, 36]. Furthermore, little is known about the biological mechanisms responsible for the rise in 
CRC with aging. Few studies have explored that the molecular profiles of CRC patients have been 
shown to differ between various age groups of CRC [21-25]. Whether patients within these various 
age groups have a different biological behavior remains controversial, for example, if some biomarkers 




The Evaluation of Genomic Applications in Practice of Prevention (EGAPP) recommended screening 
deficient mismatch repair (MMR) status for all CRC patients in 2009 [26]. MMR proteins are nuclear 
enzymes which correct mismatched nucleotides and insertion-deletion loops (IDLs) during DNA 
replication [27]. It was indicated that Stage II CRC patients with dMMR have a better outcome [28]. 
Some current studies have shown that CRCs with dMMR were more prevalent in younger patients [29, 
30]. Despite these early findings about MMR status, the association of OS for age of disease onset and 
MMR status in CRC patients is still not clear.  
In this current study, we sought to find the association of MMR status based on age and disease 
outcomes in advantage of the recommendations of the EGAPP to test MMR status [26]. We performed 
systematic IHC screening for MLH1, MSH2, MSH6 and PMS2 proteins in a large number of Chinese CRC 
patients assessed in our institute since 2011. 
Another clinical factor that we also wanted to explore is the location of the primary CRCs, which might 
be useful as a prognostic factor. Different CRC locations are derived from various embryonic tissues. 
The right colon, which includes cecum, ascending colon, and proximal two thirds of the transverse 
colon, is derived from the embryonic midgut. The left colon includes distal one third of the transverse 
colon, descending colon, sigmoid colon, and rectum, which is derived from the embryonic hindgut 
[37]. Some recent studies have indicated that the clinical characteristics and biological factors for CRC 
differ across these different locations [38-41]. One study has indicated that the primary tumor 
location could serve as prognostic factor in metastatic CRC [42]. Some studies have shown a 
correlation between patients’ gender and tumor location [43, 44]. Tumor location and age of onset 
are two important clinical characteristics for CRC patients. To date, only few studies have evaluated 
the correlations between these two factors to the prognosis of CRC. It has been previously reported 
that early-onset right colon cancers were a subset for most Lynch Syndrome cases; this group of 
patients were with earlier stages of disease at diagnosis and had better prognosis [45]. In another 
study, Bax/Bcl-2 ratio showed decreased levels in CRC patients older than 50 and in colon compared to 
rectal cancer [46].  
 
Currently, the associations between biological, clinical features and tumor locations have been made. 
Mucinous histology, wild type p53, high microsatellite instability and BRAF mutation tend to be found 
in right colon [47-49]. In contrast, left colon cancers are frequently found to be with chromosomal 
instability [48]. Rectal cancers tend to be more frequently associated with lung metastases compared 
with colon cancers [50]. While approximately 50 % of the CRC occur in rectal and sigmoid area, during 
the past decades it found a shift towards right colon. However, the impact of this change in tumor 
location to CRC prognosis has not yet been completely analyzed. The age of tumor onset is also 
considered as an important clinical factor in regard to overall survival of CRCs. Many studies have 
demonstrated that the incidence of CRC increases significantly with advancing age. However, the 
overall viewpoint that age is a significant prognostic factor in CRC has been controversial. Various 
studies have reported poorer prognosis among young patients with CRC [51-53].  
 
CRCs with dMMR tend to be located in proximal colon and have poor differentiation with increased 
numbers of lymph nodemetastases compared with CRCs with pMMR [54]. Previous studies have 
shown that right colon cancers are associated with worse prognosis than left colon and rectal cancers 
[55]. This finding would appear to be contrary with observations that right colon cancers are more 
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likely to be dMMR [56]. To date, only few studies have looked for a relationship between MMR status 
and prognosis of CRC by tumor locations [57-59].  
 
Increasing studies have shown that the biological profiles of CRCs may differ across the tumor location 
[60-62], which suggests that the mechanism of CRC development can differ across the tumor location 
[63, 64]. While right colon and left colon cancers are frequently studied in combination with each 
other, and in combination with those arising in the rectum, only a few studies have looked at the 
combination of tumor location and stage. In one earlier study, it was reported that tumor location was 
a strong predictor of high T, N and stages of disease [65]. In yet another study looking at disease 
staging and tumor location Stage II right colon cancers were shown to exhibit higher microsatellite 
instability indicating that tumor location may affect differential responses to cancer therapy [66]. It 
was reported that patients with right side colon cancer were older, more often females and had a 
poorer prognosis than patients with left side colon cancer [67]. Currently, only few studies have 
evaluated the correlation between age of tumor onset and tumor location with regard to the overall 
survival of CRCs [68, 69].  
 
To date, there has been no large-scale analysis to investigate the combined impact of Ki67, MMR 
status, tumor location and age of disease onset with regard to the overall survival of CRC. Therefore, 
we analyzed the association of CRC overall survival, expression of Ki67, MMR status and the age of 








Weltweit treten etwa 1 Million neue Fälle von Kolorektalkarzinomen pro Jahr auf und es handelt sich 
um die dritthäufigste Krebsart bei Männern und die zweithäufigste bei Frauen. Obwohl neueste 
Fortschritte in der Behandlung die Prognose verbessert haben, machen CRCs immer noch 8 % aller 
Krebserkrankungen aus [1-3]. Die Forschung hat gezeigt, dass die meisten CRCs in kolorektalen 
Polypen entstehen, bevor sie sich zu malignen Erkrankungen entwickeln. Daher kann die Resektion der 
adenomatösen Polypen durch Koloskopie helfen, um CRCs zu verhindern [4]. Die Inzidenz von CRC 
wurde mit zunehmendem Alter assoziiert. CRCs können bei jungen Leuten auftreten, aber etwa 90 % 
der CRCs werden nach dem 40. Lebensjahr diagnostiziert und die Inzidenz steigt nach diesem Alter 
noch schneller an. Darüber hinaus gibt es für ältere Patienten mit CRC einzigartige 
Behandlungsmethoden [5]. Es ist zwar möglich mithilfe von verbesserten Screeningmethoden CRC 
vollständig zu verhindern. Die Biomarker und klinischen Faktoren von CRC zu untersuchen, die zur 
Optimierung von Diagnose- und Behandlungsschemata führen können, ist unerlässlich. 
 
Ein gemeinsames Merkmal aller Krebsarten ist das Ungleichgewicht der proliferativen Aktivität und 
des Zelltods. Ki67 ist ein Antigen, das sich im Kern befindet. Der monoklonale Antikörper von Ki67 
erkannte das Antigen von der G1 bis zur M-Phase der Zellproliferation, fehlt aber bei ruhenden Zellen 
(G0). Daher ist Ki67 ein hervorragender Marker, um den Wachstumsanteil der Tumorzellen zu 
bestimmen, und ebenso könnte er vermutlich den klinischen Prozess widerspiegeln [6]. Viele Studien 
haben eine prädiktive Funktion von Ki67 bei Brustkarzinomen und neuroendokrinen Tumoren gezeigt 
[7-9]. Die Quantifizierung der Ki67-Expression als Ki67-Markierungsindex (Ki67-Li) wurde bei 
Lebermetastasen von CRC signifikant höher nachgewiesen [10]. Die Ki67-Färbung der Kernbiopsien 
des Lymphknotens war signifikant mit einer schlechten Prognose von CRC assoziiert, die Kernfärbung 
von Ki67 zeigte eine verminderte Konzentration an Rektalkarzinomen mit Chemotherapie mit 
Cetuximab [11, 12, 14]. Höheres Ki67-Li wurde als Biomarker beobachtet, um das Nierenzellkarzinom 
(RCC) mit hohem Risiko für Metastasen zu erkennen [13]. Ki67 wurde in der proliferativen basalen 
Hälfte der Krypta stark exprimiert und war im Vergleich zu Nicht-UC-Kontrollproben signifikant erhöht 
[15, 16]. In CRCs hat die Analyse von Ki67 verschiedene Muster in Verbindung mit Patientenalter, 
pathologischer Tumordifferenzierung und Lymphknotenmetastase gezeigt [17-20]. Allerdings stimmen 
nicht alle Studien mit den Assoziationen zwischen Ki67-Li und klinikopathologischen Informationen für 
CRCs überein. Wir wollten untersuchen, ob die Beurteilung von Ki67 auch dazu beitragen könnte, die 
Prognose für Patienten mit CRC genauer zu definieren. 
 
Die Vorstellung, dass das Alter ein signifikanter prognostischer Faktor in CRC sein kann, bleibt 
umstritten. Einige Studien haben eine schlechtere Prognose für jüngere Patienten mit CRC gezeigt 
[31-34]. Im Widerspruch dazu haben andere Autoren gezeigt, dass jüngere Patienten mit CRC bessere 
Prognosen im Vergleich zu älteren haben [35, 36]. Darüber hinaus ist wenig über die biologischen 
Mechanismen,  die für den Anstieg der CRC mit dem Alter verantwortlich sind, bekannt. Nur wenige 
Studien haben untersucht, ob sich die molekularen Profile von Patienten mit CRC bei verschiedenen 
Altersgruppen unterscheiden [21-25]. Ob die Patienten innerhalb dieser verschiedenen Altersgruppen 





Die Evaluation von genomischen Anwendungen in der Praxis der Prävention (EGAPP) hat das 
Screening von defizienten Mismatch-Reparatur (MMR) Status für alle CRC Patienten im Jahr 2009 
empfohlen [26]. MMR-Proteine sind Nukleus-Enzyme, die bei der DNA-Replikation nicht 
übereinstimmende Nukleotide und Insertions-Deletions-Loops (IDLs) korrigieren [27]. Es wurde darauf 
hingewiesen, dass die Stage II CRC Patienten mit dMMR ein besseres Ergebnis haben [28]. Einige 
aktuelle Studien haben gezeigt, dass dMMR bei jüngeren Patienten mit CRC häufiger waren [29, 30]. 
Trotz dieser frühen Erkenntnisse über den MMR-Status ist der Zusammenhang von OS mit dem Alter 
bei Krankheitsbeginn und dem MMR-Status bei CRC-Patienten noch nicht klar. 
 
In unsere Studie haben wir versucht, den Zusammenhang mit dem MMR-Status auf der Grundlage von 
Alters- und Krankheitsresultaten nach den Empfehlungen des EGAPP zu finden, um den MMR-Status 
zu testen [26]. Wir haben systematische IHC-Screening für MLH1-, MSH2-, MSH6- und PMS2-Gene an 
einer großen Anzahl von chinesischen CRC-Patienten in unserem Institut seit 2011 durchgeführt und 
bewertet. 
 
Ein weiterer klinischer Faktor, den wir auch erforschen wollten, ist die Lokalisation der primären CRCs, 
die als prognostischer Faktor nützlich sein könnte. Verschiedene CRC-Lokalisationen werden aus 
verschiedenen embryonalen Geweben entgenommen. Der rechte Kolon, der Cecum, den 
aufsteigenden Kolon und proximal zwei Drittel des transversalen Kolon enthält, wird aus dem 
embryonalen Middarm abgeleitet. Der linke Kolon schließt ein distales Drittel des transversalen Kolon 
ein, den absteigenden Kolon, Sigmoiddarm und Rektum, das aus dem embryonalen Enddarm stammt 
[37]. Einige neuere Studien haben gezeigt, dass sich die klinischen Merkmale und biologischen 
Faktoren für CRC an diesen verschiedenen Standorten unterscheiden [38-41]. Eine Studie hat gezeigt, 
dass die primäre Tumorlokalisation als prognostischer Faktor im metastatischen CRC dienen könnte 
[42]. Einige Studien haben eine Korrelation zwischen dem Geschlecht und dem Tumor der Patienten 
gezeigt [43, 44]. Tumorlokalisation und Alter bei Krankheitsbeginn sind zwei wichtige klinische 
Merkmale für CRC-Patienten. Bisher haben nur wenige Studien die Korrelationen zwischen diesen 
beiden Faktoren für die Prognose von CRC ausgewertet. Es wurde bereits berichtet, dass jüngere 
Patienten mit rechtem Kolonkarzinom eine Untermenge für die meisten Lynch-Syndrom-Fälle waren, 
diese Gruppe von Patienten waren in frühren Stadien der Krankheit bei der Diagnose und hatten eine 
bessere Prognose [45]. In einer anderen Studie zeigte das Bax / Bcl-2-Verhältnis ein verringertes 
Niveau bei CRC-Patienten, die älter als 50 waren, sowie bei Kolonkarzinomen im Vergleich zu 
Rektumkarzinomen [46]. 
 
Derzeit hat man die Zusammenhänge zwischen Biomarkern, klinischen Merkmalen und 
Tumorlokalisation untersucht. Muzinöse Histologie, Wildtyp p53, hohe Mikrosatelliteninstabilität und 
BRAF-Mutation neigen dazu, im rechten Kolon aufzutreten [47-49]. Im Gegensatz dazu sind linke 
Kolonkarzinome häufig mit chromosomaler Instabilität zu finden [48]. Rektale Karzinome treten 
häufiger zusammen mit Lungenmetastasen als mit Kolonkarzinomen auf [50]. Während etwa 50% des 
CRC im rektalen und sigmoiden Bereich auftreten, fand in den vergangenen Jahrzehnten eine 
Verschiebung zum rechten Dickdarm statt. Allerdings ist die Auswirkung dieser Veränderung der 
Tumorposition auf die CRC-Prognose noch nicht vollständig analysiert worden. Das Alter bei 
Tumorbeginn wird auch als wichtiger klinischer Faktor für das Gesamtüberleben von CRCs angesehen. 
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Viele Studien haben gezeigt, dass die Inzidenz von CRC mit zunehmendem Alter deutlich zunimmt. 
Allerdings ist die allgemeine Sichtweise, dass das Alter ein signifikanter prognostischer Faktor in CRC, 
umstritten. Verschiedene Studien haben über eine schlechtere Prognose bei jungen Patienten mit CRC 
berichtet [51-53]. 
 
CRCs mit dMMR neigen dazu, sich im proximalen Kolon zu befinden und haben eine schlechte 
Differenzierung mit einer erhöhten Anzahl von Lymphknotenmetastasen im Vergleich zu CRCs mit 
pMMR [54]. Frühere Studien haben gezeigt, dass die rechte Kolonkarzinome mit einer schlechteren 
Prognose assoziiert sind als linke Kolon- und Rektalkarzinome [55]. Diese Feststellung scheint den 
Beobachtungen zu widersprechen, dass mehr rechte Kolonkarzinome mit dMMR auftreten [56]. 
Bisher haben nur wenige Studien einen Zusammenhang zwischen dem MMR-Status und der Prognose 
von CRC in Bezug auf Tumorlokalisation gesucht [57-59]. 
 
Immer mehr Studien haben gezeigt, dass sich die biologischen Profile von CRCs durch die 
Tumorlokalisation unterscheiden können [60-62], was darauf hindeutet, dass sich der Mechanismus 
der CRC-Entwicklung durch die Tumorlokalisation unterscheiden kann [63, 64]. Während rechte und 
linke Kolonkarzinome häufig in Kombination miteinander untersucht werden und in Kombination mit 
denen, die im Rektum entstehen, haben nur wenige Studien die Kombination von Tumorlokalisation 
und Stadium untersucht. In einer früheren Studie wurde berichtet, dass die Tumorposition ein starker 
Prädiktor für hohe T, N und Stadien der Erkrankung war [65]. In einer weiteren Studie, die sich auf die 
Stadien und die Tumorlokalisation stützt, wurde gezeigt, dass die Dickdarmkrebserkrankungen eine 
höhere Mikrosatelliteninstabilität aufweisen, was darauf hinweist, dass die Tumorposition 
unterschiedliche Auswirkungen bei der Krebstherapie haben kann [66]. Es wurde berichtet, dass 
Patienten mit rechten Kolonkarzinomen älter waren, häufiger Frauen waren und eine schlechtere 
Prognose als Patienten mit linken Kolonkarzinomen haten [67]. Derzeit haben nur wenige Studien die 
Korrelation zwischen dem Alter bei Krankheitbeginn und der Tumorposition hinsichtlich des 
Gesamtüberlebens von CRCs untersucht [68, 69]. 
 
Bisher gab es keine groß angelegte Analyse, um die kombinierten Auswirkungen von Ki67, 
MMR-Status, Tumorort und Alter bei Krankheitsbeginn im Hinblick auf das Gesamtüberleben von CRC 
zu untersuchen. Daher analysierten wir den Zusammenhang von CRC mit Gesamtüberleben, Ausdruck 
von Ki67, MMR-Status und Alter bei Krankheitsbeginn, Tumorlokalisation mit großen Daten nach der 
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Introduction
Colorectal cancer (CRC) is the third most common cancer in 
men and the second most common cancer in women worldwide 
[1]. Data collected in 2008 showed that worldwide there were over 
1.23 million new cases, and over 608,000 patients died from CRC 
that year [2]. Several factors influence the prognosis, including 
clinical, histopathological, and biological factors related to the 
stage of the CRC tumor. Therefore, investigations into the molecu-
lar mechanisms of CRC that can lead to novel biomarkers to opti-
mize diagnosis and/or treatment regimens are essential. 
Ki67 expression has been shown to be strictly associated with 
cell proliferation. During interphase, the Ki67 antigen can be ex-
clusively detected within the cell nucleus, whereas in mitosis most 
of the protein relocates to the chromosomal surface. Ki67 protein 
is present during all active phases of the cell cycle (G1, S, G2, and 
mitosis), but is absent from resting cells (G0). Because of these 
qualities, Ki67 is an excellent marker to determine the growth frac-
tion of a given cell population, and likewise it could mark growing 
tumor cells [3].
Ki67 expression analysis is already used to estimate the progno-
sis of breast cancer and neuroendocrine tumors due to its expres-
sion pattern restricted to phases of the cell cycle in differentiating 
cells [4–6]. It was reported that liver metastases of CRC demon-
strated a significantly higher Ki67 labeling index (Ki67-Li) [7]. 
Ki67 expression was found to be significantly higher in tumor tis-
sues than in peritumoral tissues, and Ki67 levels were significantly 
associated with lymph node metastasis and poor prognosis of CRC 
[8]. However, some studies have shown that Ki67 has no correla-
tion with patient survival [9, 10]. We set out to investigate whether 
assessment of Ki67 could also help to more accurately define the 
prognosis for patients with CRC. 
Keywords
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Summary
Background: Conflicting results have been reported 
about the association between the Ki67 labeling index 
(Ki67-Li) and clinical outcome in patients with colorectal 
cancer (CRC). Patients and Methods: Ki67 expression 
was assessed by immunohistochemistry (IHC) in 2,233 
consecutive CRC cases. Results: We determined 992 
cases to have a low and 1,241 cases to have a high Ki67-
Li (representing an approximately 44–56% breakdown in 
distribution between low versus high patients desig-
nated by phenotype). Stage III patients with a high Ki67-
Li had higher 3-year disease-free survival (DFS) and 
overall survival (OS) than those with a low Ki67-Li (DFS 
70 vs. 61%; p = 0.02 and OS 75 vs. 64%; p = 0.008). We 
also found significantly improved 3-year progression-
free survival (PFS) for stage IV patients in the high ver-
sus the low Ki67-Li group (PFS 14 vs. 10%; p = 0.02). Yet, 
we found no statistical differences in prognosis for stage 
I and II patients and in OS for stage IV patients between 
high versus low Ki67-Li (p > 0.05). Conclusion: Our re-
sults suggest that high Ki67-Li can be an independent 
prognostic biomarker to aid the assessment of patient 
outcomes in both stage III and IV CRC.
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Patients and Methods
Patients
The ethics committee of the Sun Yat-sen University Cancer Center ap-
proved this study, and informed consent was obtained from all patients at the 
beginning of the study. A total of 4,500 histologically confirmed CRC patients 
were recruited and 2,233 tumor tissues were obtained after operation for analy-
sis from the Sun Yat-sen University Cancer Center between May 2011 and May 
2016. All patients were of Chinese origin. The clinical and family histories of 
each patient were reviewed. Finally, 2,233 cases were selected for analysis fol-
lowing the outlined strict exclusion criteria: age less than 18 years and older 
than 85 years, severe complication, multiprimary cancer, synchronous and me-
tachronous CRC, family history (first-degree and second-degree relatives with 
any cancer), familial adenomatous polyposis, and death not from tumor-related 
causes. The primary tumor site was categorized as proximal colon if the tumor 
was located above the splenic flexure or distal colon if it was located at or below 
the splenic flexure and rectum. Stage I (T1–2 N0) and stage II (T3–4 N0) CRC 
patients without high-risk clinical features (e.g. T4 stage, bowel perforation or 
clinical bowel obstruction, inadequate lymph node sampling, poorly differenti-
ated history) were treated with radical surgery or endoscopic removal of the 
tumor alone. Stage II (T3–4N0) CRC patients with high-risk clinical features 
received chemotherapy comprising capecitabine; folinic acid+5-fluorouracil 
(5-FU)+oxaliplatin (mFOLFOX); and capecitabine+oxaliplatin (XELOX). Stage 
III (TxN1–2) patients received radical surgery and 12 cycles of adjuvant mFOL-
FOX/XELOX within a 6-month period. All stage IV (T×N×M1) patients with 
local tumor complications or resectable metastases received palliative surgery 
or radical surgery. The first-line treatment for stage IV CRC was the mFOL-
FOX/FOLFIRI (folinic acid+5-FU+irinotecan) regimen. 89 patients with rectal 
cancer also received neo-chemoradiotherapy. Responses were evaluated in ac-
cordance with the RECIST guidelines. After surgery, tumor recurrence was de-
tected by physical examination, serum carcinoembryonic antigen (CEA) assay, 
and abdominal and thoracic imaging; patients were monitored every 3–6 
months for the first 3 years, every 6 months for the following 2 years, and then 
annually for patients surviving beyond 5 years. The duration of follow-up was 
defined as the time between surgery and disease recurrence, death, or last hos-
pital contact (scheduled follow-up or telephone contact). The cutoff date for 
this analysis was May 2016. The median follow-up time for living patients in 
this study was 4.3 years. 
Immunohistochemical Staining for Ki67
All diagnosed CRC patients, independent of clinical criteria, were prospec-
tively tested using IHC for the expression of MMR proteins on the second day 
after operation. Blocks of formalin-fixed, paraffin-embedded adenocarcinoma 
tissue comprising an area of normal colorectal mucosa adjacent to the tumor 
were selected in each case. Staining for Ki67 tissue expression was performed 
using the primary anti-Ki67 antibody (1: 50 clone MIB-1; Dako, Tokyo, Japan). 
The Ki67-Li was calculated for each sample as the percentage of positively 
stained tumor cells among all counted tumor cells. Immunostained sections 
were evaluated by 2 pathologists blinded to the patients’ clinical characteristics. 
Discordant cases were reviewed by a third pathologist to reach a consensus. 
Ki67 had a moderate to intense reaction in most cases, both in well-differenti-
ated adenocarcinomas and in moderately or poorly differentiated tumors. Rep-
resentative examples of immunostaining are shown in figure 1. The mean per-
centage of positively stained cells for all cases was 47%. In our study, a percent-
age of < 50% positively stained tumor cells among all counted tumor cells was 
considered a low Ki67-Li, and a percentage of ?  50% was considered a high 
Ki67-Li, which was in concordance with previous studies [11]. 
Statistical Analysis
Data are described as frequencies given in percentage values. The differ-
ences in distribution between the variables examined were assessed with the Χ2 
or the Fisher’s exact test. The primary end point used in the analysis was dis-
ease-free survival (DFS) defined as the time from the date of surgery to the first 
event (local or distant disease recurrence), or progression-free survival (PFS) 
calculated as the time from the start of surgery to clinical or radiological pro-
gression. Patients who were alive and relapse-free at the last contact were cen-
sored at the time of last follow-up. Overall survival (OS) was defined as the time 
elapsed from the date of surgery until tumor-induced death. Surviving patients 
were censored at the time of last follow-up. Median follow-up and 95% confi-
dence intervals (CI) were calculated using the reverse Kaplan-Meier method. 
The survival curve was estimated using the Kaplan-Meier method and com-
pared using the log-rank test. Univariate and multivariate Cox proportional 
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hazards models were used to explore associations between Ki67-Li, location, 
age, stage, differentiation grade, and gender. The score and likelihood ratio test 
p  values were used to test the statistical significance of each covariate in the 
univariate and multivariate Cox models, respectively. All statistical tests were 
two-sided, and p values ? 0.05 were considered statistically significant. Statisti-
cal analyses were performed using SPSS software (IBM Corp., Armonk, NY, 
USA).
Results
Of the 2,233 CRC patients evaluated, 992 were found to have a 
low Ki67-Li with an overall prevalence of 44.4%. 1,241 were found 
to have high Ki67 expression with a prevalence of 55.6%. This se-
lected patient population included 1,316 males and 917 females of 
which 32.8 and 22.8%, respectively, were found to present with a 
high Ki67-Li while the male versus female distribution of low Ki67-
Li was 26.2 and 18.3%, respectively. Detailed clinicopathological 
information for the patients included in this study is shown in 
table 1. In addition, we found that a high Ki67-Li was more likely 
to be noticed in the right (59.6%) or left (60.3%) colon versus the 
rectum (49.9%) (p <  0.001), and in older (40–59 years, 56.3%; 
60–85 years, 56.9%) versus younger (20–39 years, 46.3%; p = 0.028) 
patients. Gender, cancer stage, T (tumor) stage, N (lymph node) 
stage, M (metastasis) stage, and pathological differentiation 
showed no statistical differences in univariate Cox analysis (p 
> 0.05) for Ki67 expression. All parameters were dichotomy varia-
bles. Among the variables analyzed in the multivariate Cox model, 
age (hazard ratio (HR) 2.29, 95% CI 2.23–2.33, p = 0.025) and loca-
tion (HR 2.36, 95% CI 2.31–2.38, p = 0.020) were significantly as-
sociated with DFS. Age (HR 2.15, 95% CI 2.09–2.18, p = 0.022) and 
location (HR 2.40, 95% CI 2.36–2.43, p = 0.018) also had a statisti-
cally significant correlation with OS. 
Assessment of Ki67-Li as Prognostic Marker
Patients with stage III CRC and a high Ki67-Li had a statistically 
significant improvement in DFS (70%) and OS (75%) compared to 
patients with low Ki67-Li tumors (DFS 61%; HR 0.72, 95% CI 
0.55–0.95, p = 0.02 and OS 64%; HR 0.68, 95% CI 0.51–0.91, p = 
0.008). We also found significant improvement in the 3-year PFS 
for stage IV patients in the high Ki67-Li group (PFS 14%) versus 
the low Ki67-Li group (PFS 10%) (HR 1.23, 95% CI 1.04–1.57, p = 
0.02). However, OS showed no statistical difference in stage IV pa-
tients with high Ki67-Li tumors (OS 19%) versus low Ki67-Li tu-
mors (OS 18%) (HR 1.22, 95% CI 0.99–1.51, p = 0.06). From the 
analysis of stage I patients, we found no differences in the 3-year 
DFS or OS between high Ki67-Li patients versus those with a low 
Ki67-Li (DFS 94 vs. 93%; HR 0.84, 95% CI 0.35–2.03, p = 0.70 and 
OS 95 vs. 93%; HR 0.69, 95% CI 0.27–1.74, p = 0.43). Likewise, no 
difference was found in the 3-year DFS and OS of high versus low 
Ki67-Li stage II patients (DFS 83 vs. 78%; HR 0.77, 95% CI 0.57–
1.05, p = 0.09 and OS 85 vs. 81%; HR 0.82, 95% CI 0.59–1.13, p = 
0.22). The survival plots for Ki67-Li are shown in figure 2. 
Discussion
Here, we evaluated the expression of Ki67 in CRC tissues and 
whether assessment of the Ki67-Li could be a valuable prognostic 
tool in this disease. We found that a high Ki67-Li appeared to be an 
independent and good prognostic biomarker for survival in stage 
III and IV CRC patients while it provided no evidence for a prog-
nostic effect in stage I or II CRC patients. The reasons for the dis-
crepancies between the effect of Ki67 expression in the various 
CRC stages are not clear. However, the differences may account for 
the many roles of Ki67 in cell growth and regulation. 
It has been previously shown that the rate of tumor cell prolif-
eration can be assessed by detecting the fraction of cells with nuclei 
expressing Ki67 [6]. The Ki67 antigen binds to the nuclei of prolif-
erating cells throughout the cell cycle, except during the G0 and 
early G1 phases, marking cellular expansion [12]. Monitoring of 
the Ki67 protein has already been used as a clinical predictor for 
the prognosis of breast cancer and neuroendocrine tumors due to 
its expression pattern restricted to growth phases of the cell cycle 
found in differentiating cells [4, 5]. Nuclear staining of Ki67 was 
also shown to be significantly associated with disease-specific sur-
vival in a multivariate model of clear cell renal cell carcinoma and 
provided the ability to predict disease outcome [13]. It has also 
been reported that neoadjuvant chemoradiotherapy with cetuxi-
mab decreased the levels of Ki67-Li in rectal cancer [14]. With re-
gard to colon tissue, Ki67 was found to be highly expressed in the 
proliferative basal half of the crypt [15]. Also, it has been shown 
that Ki67 was significantly elevated in ulcerative colitis (UC) co-
lons compared to non-UC control samples, indicating that prolif-
eration is enhanced in UC colonic mucosa [16]. With regard to 
CRC itself, it has been reported that Ki67 expression correlates 
with patient age, pathological tumor differentiation, and lymph 
node involvement [17]. In addition, a strong correlation between 
Ki67 expression has also been seen in all levels of epithelial dyspla-
sia and tumor grades [18]. In another study, Ki67-Li was found to 
significantly correlate with lymph node metastasis, but not tumor 
size, age, or gender, in rectal adenocarcinomas [19]. It has also 
been shown that Ki67 expression is not related to atypia [20].
From our large dataset of Chinese CRC patients studied here, 
we found that high Ki67-Li correlated with old age and better sur-
vival for stage III or IV colon cancers, but not with gender, tumor 
stage, or pathological differentiation. Overall, the results of our at-
tempt to find an association between Ki67-Li and prognosis for the 
general population of patients with CRC were conflicting. Incon-
sistent effects of Ki67 expression with regard to patient outcomes 
also appear to have been evidenced in other studies. A previous 
study using Kaplan-Meier survival analysis showed that survival 
was significantly shorter for CRC patients with higher expression 
of Ki67 versus lower [21, 22]. Yet, lower TNM and Dukes stage and 
higher Ki67 expression and presence of Ki67 hot spot areas in his-
topathological samples in rectal carcinoma were associated with 
better survival rates [23]. High Ki67 expression was also found to 
correlate well with response of chemoradiation therapy in locally 
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study showed that patients with high tumor regression actually had 
significantly lower Ki67 expression within their tumors than non-
responders [25]. Finally, well-differentiated adenocarcinomas from 
liver cancers were found to have a high number of low Ki67-Li ves-
sels that might account for differences in tumor growth [26]. 
Many of these earlier studies on the effects of Ki67 expression 
utilized only a small number of cases in their analysis. A more re-
cent study in CRC that analyzed 1,653 cases reported that high 
Ki67 expression is an independent prognostic marker for better 
survival [27]. The results of this earlier study are in slight contrast 
to those of the current study. In our study, we also found a high 
Ki67-Li to be an good independent prognostic biomarker but only 
for stage III or IV CRC patients. We found no prognostic effect for 
Ki67 indexing in stage I or II CRC patients. 
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One of the criteria that might account for the above differences 
is the classification of Ki67 indexing. The previous study stratified 
the patient groups into 3 categories of low, moderate, and high 
whereas we used only 2 designations of either high or low. Only 
17% of the previous study’s 1,653 patients were considered to have 
a high Ki67-Li. Second, our study was conducted in only 1 hospital 
in China, and this population may not be comparable to the previ-
ous study’s patient population nor does it necessarily reflect the 
entire population of China. Finally, CRC is a disease induced by 
multiple biological, genetic, and environmental factors that could 
account for differences in tumor response, and each of these ele-
ments should be examined in future studies. 
Conclusion
Our data demonstrate that patients with a high Ki67-Li have a 
statistically significant reduction in their rates of tumor recurrence 
as well as better survival rates compared to patients with a low 
Ki67-Li for stage III CRC. While no statistically significant differ-
ences were found for patients with stage I and II tumors and a high 
Ki67-Li, for stage IV CRC patients Ki67-Li was an effective prog-
nostic factor predicting PFS but not OS. Finally, we demonstrated a 
close correlation between high Ki67-Li and old age and colon can-
cer. This study provides further population-specific evidence for 
Ki67 expression in CRC and use of Ki67-Li monitoring for patient 
management.
Disclosure Statement
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Fig. 2. Disease-free survival (DFS) and overall survival (OS) according to Ki67 expression in colorectal carcinoma (CRC) stage I–IV.
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The development of colorectal cancer (CRC) can be a 
slow process, with early stages of disease often presenting 
with no clinical symptoms to the patient. It has been 
indicated that most CRCs are adenocarcinomas arising 
from noncancerous adenomatous polyps [1,2]. Like many 
other types of cancer, CRC has been found to have an 
associated higher incidence with increasing age. The risk 
of CRC has a marked increase in occurrence after reach-
ing 40 years of age and incidence continues to increase 
even more rapidly after this age. Overall, the risk of CRC 
doubles with each succeeding decade of age, and continues 
to rise exponentially in incidence with age [3].
Little is known about the precise biochemical mecha-
nisms responsible for the rise in CRC with aging. Many 
possible causes for this increase in CRC incidence have 
been suggested. One model of CRC progression proposed 
by Vogelstein et al. indicates that malignancy arises as a 
result of accumulation of mutations in tumor suppressor 
genes and oncogenes [4]. Indeed, the molecular profiles 
of CRC patients have been shown to differ between vari-
ous age groups of patients examined [5–7]. Whether 
patients within these various age groups have a different 
ORIGINAL RESEARCH
Impact of age and mismatch repair status on survival in 
colorectal cancer
Pan Li1, Zhi-Tao Xiao2, Todd A. Braciak1, Qing-Jian Ou2, Gong Chen2 & Fuat S. Oduncu1
1Department of hematology and oncology, Medizinische Klinik und Poliklinik IV, Ludwig Maximilians University, Munich, Germany
2Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, 
distribution and reproduction in any medium, provided the original work is properly cited.
Keywords
Age, biomarker, colorectal cancer, MMR 
status, prognosis
Correspondence
Fuat S. Oduncu, Department of hematology 
and oncology, Medizinische Klinik und 
Poliklinik IV, Ludwig Maximilians University, 
Ziemssenstr. 1, D-80336 Munich, Germany. 
Tel: +49-(0)-89-4400-52205;  
Fax: +49-(0)-89-4400-54412;  
E-mail: fuat.oduncu@med.uni-muenchen.de
and
Gong Chen, Department of Colorectal 
Surgery, State Key Laboratory of Oncology in 
South China, Sun Yat-sen University Cancer 
Center, East Dongfeng Road 651, D-510060 
Guangzhou, China.  
Tel: +86-13500030531;  
Fax: +86-(0)-20-87343584;  
E-mail: chengong@sysucc.org.cn
Funding information
No funding information provided.
Received: 19 September 2016; Revised: 5 
December 2016; Accepted: 14 December 2016
Cancer Medicine 2017; 6(5):975–981
doi: 10.1002/cam4.1007
Abstract
Previous studies have suggested that deficiencies in mismatch repair genes 
(dMMR) often occur in patients with colorectal cancer (CRC) and contribute 
to disease etiology. Here, we looked for a correlation of MMR status to disease 
outcomes from a large number of Chinese CRC patients stratified by the age 
of onset of disease. A total of 2233 CRC patients were analyzed and tissue 
biopsies of surgically removed tumors scored for MMR gene status. The patient 
distribution after classification consisted of 188 younger aged patients (20–39 years 
of age), 1024 middle aged patients (40–59 years of age), and 1020 older aged 
patients (60–85 years of age). In this analysis, the expression of four MMR 
genes was assessed by immunohistochemistry (IHC). We found that the young 
group of CRC patients with dMMR had higher overall survival (OS) than the 
young group of patients with proficient MMR (pMMR) (77% vs. 56%, P = 0.03). 
Middle- aged patients with dMMR also had higher OS than middle- aged group 
patients with pMMR (78% vs. 68%, P = 0.012). However, we found no statisti-
cal difference in OS between dMMR and pMMR status in the older group of 
patients (75% vs. 71%, P = 0.224). Finally, the middle- and older- aged group 
set of patients had higher OS than the young group of patients (69% vs. 71% 
vs. 59%, P = 0.008). These data demonstrated that the age of disease onset can 
be an important factor to help evaluate the prognosis of CRC when combined 
with the analysis of MMR status within tumor biopsied tissue.
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biological behavior including MMR activity remains 
controversial.
MMR genes correct mismatched nucleotides and inser-
tion–deletion loops (IDLs) in DNA caused by polymerase 
errors, chemical modifications, and recombination between 
heterologous DNA sequences [8]. It was previously dem-
onstrated that stage II CRC patients with dMMR have a 
better prognosis and it was indicated that some patients 
may actually be harmed by 5- FU treatment [9]. More 
recent studies have found that CRC tumors with dMMR 
were more prevalent in younger patients [10,11]. Despite 
these early findings about MMR status, there still has 
been no conclusive study to prove an association with 
overall survival (OS) for age of disease onset and MMR 
status in CRC patients.
In this study, we sought to find if difference in MMR 
status based on age could be useful to identify groups 
of patients that would have better disease outcomes. 
Following the recommendations of the EGAPP [12], we 
performed systematic immunohistochemistry (IHC) 
screening of CRC tumor tissues looking for microsatellite 
instability of patients. Here, we had access to a large 
number of Chinese CRC patients who were operated on 
to remove their primary tumors and whose tissues were 
assessed in our institute since 2011. Our findings indicate 
that the combined analysis of age of onset and MMR 
status could provide some prognostic information about 
these CRC patient outcomes.
Materials and Methods
Patients
The ethics committee of Sun Yat- sen University Cancer 
Center approved this study and informed consents for 
all patients were obtained at the beginning of the study. 
A total of 4500 patients with histologically confirmed CRC 
tumors were recruited from the Sun Yat- sen University 
cancer center between May 2011 and May 2016 for this 
study. Clinical and familial histories for each of these 
patients were reviewed. From these recruited patients, 2233 
cases were finally selected for analysis after applying strict 
exclusion criteria that included: age less than 18 years 
and older than 85 years, severe complication, multiprimary 
cancer, synchronous and metachronous CRC, family his-
tory (first- degree and second- degree relatives had any kind 
of cancer), familial adenomatous polyposis, death not due 
to tumor- related reason, and incomplete follow- up record 
were not included for study. The primary tumor location 
site was categorized as right colon if the tumor was located 
above the splenic flexure, and left colon if it was located 
at or below the splenic flexure or as from the rectum. 
The median follow- up on surviving patients was 4.3 years.
Treatment and follow- up
Stage I (T1–2 N0) and stage II (T3–4 N0) CRC patients 
without high- risk clinical features (e.g., T4 stage, bowel 
perforation or clinical bowel obstruction, inadequate 
lymph node sampling, poorly differentiated histology) 
were treated with radical surgery or endoscopic removal 
of the tumor alone. Stage II (T3–4 N0) CRC patients 
with high- risk clinical features were recommended to 
follow the capecitabine+oxaliplatin (XELODA) treatment 
regimen. Stage III (Tx N1–2) patients were designated 
to receive radical surgery and 12 cycles of adjuvant 
mFOLFOX/XELOX regimen treatment within a 6- month 
period. All stage IV (Tx Nx M1) patients received pal-
liative surgery or radical surgery. The first- line treatment 
for stage IV CRC was mFOLFOX/FOLFIRI (folinic acid+5- 
FU+irinotecan) chemotherapy regimen. Patient clinical 
responses were evaluated in accordance with the RECIST 
guidelines. After surgery, tumor recurrence was deter-
mined by physical examination, serum carcinoembryonic 
antigen (CEA) assay, or abdominal and thoracic imaging 
taken every 3–6 months for the following 3 years after 
initial therapy, then every 6 months for the next 2 years, 
and finally followed by annual checkup. In addition, Sun 
Yat- sen University cancer center has an independent 
follow- up department. The colleagues call the patients 
or the family members regularly and register the survival 
status and health condition. The cutoff date of analysis 
for inclusion in this study was May 2016.
Immunohistochemistry
Blocks of formalin- fixed, paraffin- embedded CRC adeno-
carcinoma tissue comprising an area of normal colorectal 
mucosa adjacent to the tumor were selected in each case. 
Cases with complete nuclear loss of MMR expression in 
invasive tumor cells but with retained expression in 
inflammatory cells and/or adjacent normal tissue as posi-
tive controls were considered MMR deficient. Staining 
was performed using the following primary antibodies: 
mouse anti- human mutL homolog 1 (MLH1) (dilution 
1:150, clone OTI1C1, zhongshan jiqiao, Beijing), rabbit 
anti- human mutS homolog2 (MSH2) (dilution 1:100, 
clone ZA0622, zhongshan jiqiao, Beijing, mouse anti- 
human mutS homolog 6 (MSH6) (dilution 1:150, clone 
OTI5D1, zhongshan jiqiao, Beijing), and mouse anti- 
human postmeiotic segregation increased 2 (PMS2) (dilu-
tion 1:150, clone OTI2G5, zhongshan jiqiao, Beijing). 
Whole- tissue sections were analyzed independently by two 
pathologists and were blinded to any of the patients’ 
clinical characteristics. Any discordant cases were reviewed 
by a supplementary pathologist in order to reach a con-
sensus on the tumor characterization. Illustrative 
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immunostainings of recovered CRC tumor sections are 
shown in Figure 1.
Statistical analysis
Patient data are described in frequencies (percentages) of 
cases with the given phenotype. Differences in distribu-
tions between the variables examined were assessed by 
the χ2 or the Fisher’s exact test. The primary end point 
of the study was OS, defined as the time elapsed from 
the date of surgery until the tumor- induced death of the 
patient. Surviving patients were censored on the last follow-
 up date. Median follow- up and the 95% CI were calculated 
using the reverse Kaplan–Meier method. The survival curve 
was estimated with the Kaplan–Meier method and com-
pared using the log- rank test. The score and likelihood 
ratio test P-values were used to test the statistical signifi-
cance of each covariate in the univariate and multivariable 
Cox models, respectively. All statistical tests were two- sided, 
and P-values less than or equal to 0.05 were considered 
statistically significant. Statistical analyses were performed 
using SPSS software.
Results
A total of 2001 (89.6%) of all CRC specimens examined 
showed retained expression in tumor cells for MLH1, 
MSH2, MSH6, and PMS2 proteins. In comparison, loss 
of expression in at least one of the four MMR genes was 
found to occur in 232 of 2233 patients analyzed repre-
senting a dMMR status for 10.4% of the CRC patients 
examined. The patients analyzed included 188 patients 
(8.4%) classified as young (20–39 years old), 1024 (45.9%) 
as middle- aged patients (40–59 years old), and 1020 (45.7%) 
as older- aged patients (60–85 years old). Their median 
age at diagnosis was 58 years (ranged 18–85 years). The 
patient demographics and tumor characteristics by age 
are listed in Table 1.
In addition, we found that 55.3% of the younger patient 
group were female. With regard to dMMR status, we 
found that tumors with dMMR status tended to be noticed 
in higher incidence in younger patients (13.8%) compared 
to middle- age (12.2%) and older patients (7.9%) 
(P < 0.001). In univariate analysis, the MMR status (HR: 
1.56, 95% CI: 1.18–2.06, P = 0.002) and tumor stage 
(HR: 0.19, 95% CI: 0.16–0.23, P < 0.001) showed statisti-
cal significance. However, among the variables analyzed 
in the multivariate Cox model, only tumor stage (HR: 
0.20, 95% CI: 0.17–0.24, P < 0.001) was shown to be 
significantly associated with OS regarding the age of disease 
onset. We found that gender (HR: 0.96, 95% CI: 0.82–1.11, 
P = 0.561), tumor location (HR: 0.92, 95% CI: 0.83–1.01, 
P = 0.064), and pathological differentiation (HR: 0.97, 
95% CI: 0.84–1.12, P = 0.700) showed no statistical dif-
ferences by univariate Cox analysis (P > 0.05) regarding 
the age of disease onset.
Our most important finding in this study was that we 
could find an association for dMMR status and age of 
disease onset to OS for our Chinese CRC patients exam-
ined. As part of this analysis, we found that age alone 
had associations with OS. Here, middle- and older- aged 
patients had higher OS than younger- aged grouped patients 
(69% vs. 71% vs. 59%, HR: 1.07, 95% confidence interval 
(CI): 0.91–1.25, P = 0.008). In our results, the middle- 
(69%) and older- aged (71%) patients have similar OS with 
no significant difference. However, when the middle- and 
Figure 1. Illustrative immunostainings. Positive (upper panel) and negative (lower panel) for MLH1, MSH2, MSH6, and PMS2.
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older- aged patients are compared with younger- aged 
patients (59%), statistical significance is shown. When age 
was analyzed in conjunction with MMR status, we found 
that younger CRC patients with dMMR had higher OS 
than young patients with proficient MMR (pMMR) (77% 
vs. 56%, HR: 0.42, 95% CI: 0.19–1.02, P = 0.03). Likewise, 
we found that middle- aged patients with dMMR also had 
higher OS than middle- aged patients with pMMR (78% 
vs. 68%, HR: 0.63, 95% CI: 0.43–0.92, P = 0.012). This 
association of age with dMMR did not hold for older- age 
group patients. Here, we found no statistical difference in 
OS between dMMR and pMMR status for older- aged CRC 
patients (75% vs. 71%, HR: 0.76, 95% CI: 0.48–1.20, 
P = 0.224). Patient survival plots with regard to tumor 
location and MMR status are shown in Figure 2.
Discussion
Multiple risk factors contribute to the capacity of an 
individual to develop CRC. Disturbingly, younger- aged 
patients are more likely to be diagnosed with later stage 
disease when their cancers are discovered [13]. However, 
it is unclear whether this reflects differing biology between 
young versus older patients or simply that a low rate of 
CRC screening is performed at this young age. In our 
present Chinese population- based CRC study, we looked 
to see if age and MMR status had an impact on the 
survival of these CRC patients.
It was previously reported that younger patients have 
a higher prevalence of mucinous or signet- ring types of 
carcinoma [14,15]. Yet here, in our study, we found that 
pathological differentiation showed no statistical difference 
to OS (P > 0.05). Another study demonstrating a linkage 
to age and CRC demonstrated that the age at diagnosis 
of inflammatory bowel disease was an indicator of early 
development of CRC in inflammatory bowel disease 
patients [7].
In younger patients, CRC tend to present more com-
monly as stage III or IV disease, which may reflect dif-
fering biology in younger- aged CRC patients, but could 
Table 1. Clinicopathological characteristics of the patients.








Male 84 (3.8) 599 (26.8) 633 (28.3)
Female 104 (4.7) 425 (19.0) 388 (17.4)
Location 0.228
Right colon 52 (2.3) 243 (10.9) 226 (10.1)
Left colon 59 (2.6) 323 (14.5) 358 (16.0)
Rectum 77 (3.4) 458 (20.5) 437 (19.6)
Pathology 0.095
G1 18 (0.8) 48 (2.1) 38 (1.7)
G2 152 (6.8) 919 (41.2) 931 (41.7)
G3 0 (0.0) 5 (0.2) 13 (0.6)
Mucinous 13 (0.6) 46 (2.1) 36 (1.6)
Signet- ring 5 (0.2) 6 (0.3) 3 (0.1)
Stage <0.001
I 13 (0.6) 129 (5.8) 189 (8.5)
IIA 57 (2.6) 273 (12.2) 280 (12.5)
IIB 13 (0.6) 119 (5.3) 93 (4.2)
IIC 3 (0.1) 17 (0.8) 22 (1.0)
IIIA 6 (0.3) 25 (1.1) 24 (1.1)
IIIB 30 (1.3) 209 (9.4) 213 (9.5)
IIIC 14 (0.6) 47 (2.1) 31 (1.4)
IVA 28 (1.3) 123 (5.5) 114 (5.1)
IVB 24 (1.1) 82 (3.7) 55 (2.5)
MMR status <0.001
dMMR 26 (1.2) 125 (5.6) 81 (3.6)
pMMR 162 (7.3) 899 (40.3) 940 (42.1)
Alive 0.001
Yes 111 (5.0) 707 (31.7) 726 (32.5)
No 77 (3.4) 317 (14.2) 295 (13.2)
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also be reflective of later diagnosis because of the rarity 
of this condition in that age group, and/or less surveil-
lance in general of cancers in this age group [13]. In 
concordance with this previous study, here, we also found 
that younger patients were more likely to present as stage 
IIIB or IVB disease.
The evidence is increasing to indicate that the molecular 
profiles of CRC cells can differ in various age groups of 
patients and that this will influence the given patient’s 
disease outcome and response to therapy [5–7]. It was 
reported that CRC patients above the age of 50 showed 
decreased Bax/Bcl- 2 ratios that might differentially control 
tumor cell apoptosis between the various age groups of 
patients [5]. Also, it has been shown that peripheral blood 
leukocyte (PBL) telomere length varies according to the 
age of CRC onset, perhaps impacting immune cell func-
tions differentially [6]. With regard to MMR status, a 
more recent set of studies found that dMMR was more 
Figure 2. Overall survival (OS) according to MMR status and age in colorectal carcinoma (CRC) stage I-IV.
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prevalent in younger CRC patients [10,11]. Likewise, we 
found that tumors with a dMMR status tended to be 
more prevalent in the younger group of patients (13.8%) 
versus the middle- (12.2%) or older- aged patients (7.9%) 
(P < 0.001).
MMR corrects mismatched nucleotides and insertion–
deletion loops (IDLs) in DNA caused by polymerase 
errors, chemical modifications, and recombination 
between heterologous DNA sequences [8]. It was dem-
onstrated that stage II patients with dMMR have a better 
prognosis and may actually be harmed by 5- FU treat-
ment [9]. In our study, young CRC patients with dMMR 
had higher OS than young patients with pMMR 
(P = 0.03). We also found that middle- aged patients 
with dMMR also had higher OS than middle- aged patients 
with pMMR (P = 0.012). However, we found no sta-
tistical difference in OS between dMMR and pMMR 
status in older- aged patients (P = 0.224). While not yet 
known, these differences in disease response may be 
based upon the molecular profile or epigenetics among 
these various aged patients.
Overall, the notion that age can be a significant prog-
nostic factor in CRC has been somewhat controversial. 
Various studies have reported poorer prognosis for younger 
patients with CRC [16–19]. Yet, other authors have dem-
onstrated that younger patients with CRC surgically treated 
appeared to have a higher cancer- specific survival rate 
than elderly ones [13,19,20]. In our study here, we found 
that middle- and older- aged patients had higher OS than 
young patients (P = 0.008), indicating that again there 
is some link to age and CRC patient disease response.
In conclusion, the observation that cancer- related mor-
tality did not decrease with increasing age exemplified 
that, although elderly patients have a shorter life expectancy 
based on their age and preexistent conditions, they did 
still benefit from cancer treatment. The combination of 
age and MMR was a significant predictor of overall sur-
vival in our study, reflecting the importance of optimizing 
patient beyond treatment. The potential efficacy of age- 
tailored and molecular profiled interventions as compo-
nents of personalized care clearly need to be investigated 
further in future studies.
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Abstract
Background
The progression of colorectal cancer (CRC) may differ depending on the location of the
tumor and the age of onset of the disease. Previous studies also suggested that the molecu-
lar basis of CRC varies with tumor location, which could affect the clinical management of
patients. Therefore, we performed survival analysis looking at different age groups and mis-
match repair status (MMR) of CRC patients according to primary tumor location in an
attempt to identify subgroups of CRC that might help in the prognosis of disease.
Methods
A group of 2233 patients operated on to remove their CRC tumors were analyzed (521 with
right colon cancer, 740 with left colon cancer and 972 with rectal cancer). The expression of
four MMR genes was assessed by immunohistochemistry (IHC), independent of clinical cri-
teria. From the data collected, a predictive model for overall survival (OS) could be con-
structed for some associations of tumor location and age of onset using Kaplan-Meier,
logistic and Cox regression analysis.
Results
When tumor location was considered as the lone factor, we found no statistical difference in
overall survival (OS) between right cancer (68%), left cancer (67%) or rectal cancer tumor
locations (71%) (HR: 1.17, 95%CI (confidence interval): 0.97–1.43, P = 0.057). When age of
onset was considered, middle age (40–59 years) and older (60–85 years) patients were
found to have higher OS than younger onset cancer (20–39 years) patients (69% vs 71% vs
59%, HR: 1.07, 95% confidence interval (CI): 0.91–1.25, P = 0.008). When both age of
onset and tumor location were considered in combination as disease factors, we found that
the subgroup of patients with left colon cancer from middle age (69%) and older (67%) aged
patients had higher OS than younger (54%) patients (HR: 0.89, 95%CI: 0.68–1.16, P =
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0.048). However in patients with right colon cancers, we found no statistical difference is OS
between younger, middle age or older grouped patients (60% vs 71% vs 67%, HR: 0.84,
95% CI: 0.61–1.16, P = 0.194). With regard to rectal located cancers, we found that younger
(62%) and middle age (68) patients had lower OS than older (77%) patients (HR:1.46, 95%
CI: 1.13–1.88, P = 0.004). The rates of deficient MMR (dMMR) was 10.4%. We found no sta-
tistical difference in OS stratified by tumor locations. However, right colon cancer patients
with dMMR (86%) had higher OS than those with proficient MMR (pMMR) (63%) (HR: 3.01,
95% CI: 1.82–4.97, P<0.001). Left colon cancer patients with dMMR (76%) also had higher
OS than those with pMMR (66%) (HR: 1.67, 95% CI: 0.95–2.92, P = 0.01). Oppositely, rectal
cancer patients with dMMR (60%) had lower OS than those pMMR (68%) (HR: 0.77, 95%
CI: 0.51–1.17, P = 0.04).
Conclusions
These data demonstrate that primary tumor location can be an important factor when con-
sidered along with age of onset for the prognosis of CRC. Primary tumor location is also an
important factor to evaluate the predictive effect of MMR status for the prognosis of CRC.
Introduction
It is estimated that colorectal cancer causes over 600,000 deaths worldwide annually, which
makes this disease the fourth most common cause of cancer-related death[1,2]. Tumor loca-
tion is now being considered to be an important factor for pathogenesis of CRC. Currently,
noteworthy correlations between certain biological, clinical features and the anatomic subsites
of the tumor have been made. Right colon cancers are more likely to be characterized by
mucinous histology, high microsatellite instability, wild type p53 and BRAF mutation[3,4,5].
In contrast, left colon cancers are frequently found to be infiltrating, constricting lesions, with
a phenotype that involves chromosomal instability[4]. While rectal located cancers are known
to be more strongly associated with the presence of isolated pulmonary metastases than colon
cancer [6]. While approximately 50% of the CRC occur in rectosigmoid area, a shift in location
towards the proximal colon during the past few decades has been noted. The impact of this
shift in CRC tumor location with regard to prognosis has not yet clearly been defined.
Another factor that has been considered that might have prognostic impact is the age of dis-
ease onset. It is known that the incidence of CRC increases markedly with advancing age.
However, the overall notion that age is a significant prognostic factor in CRC has been contro-
versial. Various studies have reported poorer prognosis among young patients with CRC[7].
While other reports have demonstrated that younger patients with CRC surgically treated to
remove primary tumors appeared to have a higher specific survival rate than elderly patients
[8,9].
CRCs with dMMR have distinct clinical and pathological features that commonly include
proximal colon predominance, poor differentiation and increased numbers of tumor-infiltrat-
ing lynphonotes compared with CRCs with pMMR[10]. Most prior studies have suggested
that right colon cancers are associated with higher mortality than left colon and rectally located
cancers[11]. This finding would appear to be inconsistent with observations that right colon
cancers are more likely to be dMMR[12]. To date, only a limited number of prospective studies
have looked for a relationship between MMR status and prognosis of CRC by subsite across
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the colorectum[13,14]. Although many of these previous studies had large study populations,
many case groups became small after stratification by MMR status and tumor site were used
for analysis. While the dMMR phenotype has been reported to be up to 10-fold higher in fre-
quency as seen in sporadic proximal compared to left tumors[15], there remains a need to bet-
ter understand the epidemiologic and clinical profile of MMR status between right and left
colon or rectally located cancers. Currently, only a limited number of prospective studies have
evaluated the relation between tumor location and age of onset with regard to prognosis of
CRC [16] [17].
To date, there has been no systematical analysis looking at the combined influence of MMR
status, location and age of disease onset with regard to the prognosis of CRC. Therefore, we
analyzed the relationship of CRC overall survival, MMR status and the age of onset stratified




The ethics committee of Sun Yat-Sen University Cancer Center approved this study and the
written informed consents for all patients were obtained at the beginning of the study. A total
of 4500 histologically confirmed patients with CRC were recruited after operation from Sun
Yat-Sen University cancer center between May 2011 and May 2016. All patients were of Chi-
nese origin. The clinical and family history for each of these patients was reviewed. Finally,
2233 cases were selected for analysis after application of the following strict exclusion criteria:
patients age less than 18 years and older than 85 years, severe complication, multi-primary
cancer, synchronous and metachronous CRC, family history (first-degree and second-degree
relatives had any kind of cancer), familial adenomatous polyposis, death not due to tumor-
related reason were not included in the study. The primary tumor location was categorized as
right colon if the tumor was located above the splenic flexure or left colon if it was located at or
below the splenic flexure and rectum. The median follow-up on living patients was 4.3 years.
Treatment and follow-up
Stage I (T1–2 N0) and stage II (T3–4 N0) CRC patients without high-risk clinical features (e.g.
T4 stage, bowel perforation or clinical bowel obstruction, inadequate lymph node sampling,
poorly differentiated histology) were treated with radical surgery or endoscopic removal of the
tumor alone. Stage II (T3–4 N0) CRC patients with high-risk clinical features were recom-
mended to follow the XELODA/mFOLFOX/XELOX treatment regimen. Stage III (Tx N1–2)
patients were scheduled to receive radical surgery and 12 cycles of adjuvant mFOLFOX/
XELOX regimen treatment within a 6-month period. All stage IV (Tx Nx M1) patients
received either palliative surgery or radical surgery. The first-line treatment for Stage IV CRC
was the mFOLFOX/FOLFIRI chemotherapy regimen. Eighty-nine patients with rectal cancer
also received neo-chemoradiotherapy. Responses were evaluated in accordance with the
RECIST guidelines. After surgery, tumor recurrence was monitored by physical examination,
serum carcinoembryonic antigen (CEA) assay, and abdominal and thoracic imaging taken
every 3–6 months for the first 3 years following initial therapy, then every 6 months for the fol-
lowing 2 years, and finally from an annual check up. The duration of the patient follow-up was
defined as the time between surgery and disease recurrence, death or last hospital contact
(scheduled follow-up or telephone contact). The cutoff date for this analysis was May 2016.
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Immunohistochemistry
Blocks of formalin-fixed, paraffin-embedded adenocarcinoma tissue comprising an area of nor-
mal colorectal mucosa adjacent to the tumor were selected in each case. Cases with complete
nuclear loss of expression in invasive tumor cells with retained expression in inflammatory cells
and/or adjacent normal tissue as positive controls were considered MMR deficient. Staining
was performed using the following primary antibodies: mouse anti-human mutL homolog 1
(MLH1) (dilution 1:150, clone OTI1C1, zhongshan jiqiao, Beijing), rabbit anti-human mutS
homolog2 (MSH2) (dilution 1:100, clone ZA0622, zhongshan jiqiao, Beijing, mouse anti-
human mutS homolog 6 (MSH6) (dilution 1:150, clone OTI5D1, zhongshan jiqiao, Beijing),
and mouse anti-human postmeiotic segregation increased 2 (PMS2) (dilution 1:150, clone
OTI2G5, zhongshan jiqiao, Beijing). Whole tissue sections were read separately by two patholo-
gists blinded to the patients’ clinical characteristics. Discordant cases were reviewed by a supple-
mentary pathologist to reach a consensus. Illustrative immunostainings are shown in Fig 1.
Statistic analysis
Patient data were described as frequencies (percentages) in our analysis. Differences in distri-
butions between the variables examined were assessed with the Χ2 or the Fisher’s exact test.
The primary end point for this study was OS, defined as the time elapsed from the date of sur-
gery until tumor-induced death. Surviving patients were censored on the last follow-up date.
Median follow-up and the 95% CI were calculated using the reverse Kaplan–Meier method.
The survival curve was estimated with the Kaplan–Meier method and compared using the log-
rank test. Univariate and multivariable Cox proportional hazards models were used to explore
the association of age, location, stage, differentiation grade and gender. The score and likeli-
hood ratio test P values were used to test the statistical significance of each covariate in the uni-
variate and multivariable Cox models, respectively. All statistical tests were two-sided, and P
values less than or equal to 0.05 were considered statistically significant. Statistical analyses
were performed using SPSS software.
Results
The examined patient population included 521 (23.3%) right colon cancers, 740 (33.1%) left
colon cancers and 972 (43.5%) rectal located cancers. A total of 2001 (89.6%) CRC specimens
Fig 1. Illustrative immunostainings. Positive (upper panel) and negative (lower panel) for MLH1, MSH2, MSH6 and PMS2.
doi:10.1371/journal.pone.0172799.g001
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showed retained expression of MLH1, MSH2, MSH6 and PMS2 in tumor cells. In comparison,
loss of expression in at least one of the four MMR genes occurred in only 232 of 2233 patients
analyzed (10.4%). The results for demographics and tumor characteristics by location are listed
in Table 1.
In general, we found that colon cancers (77.1%) were more likely to be mucinous or signet-
ring phenotype tumors than rectal cancers (22.9%) (P<0.001). The OS between the four stages
of CRC showed significant differences (stage I: 94%, stage II: 83%, stage III: 70% and stage IV:
18%, HR 0.93, 95%CI: 0.65–2.38, P<0.001). With regard to tumor location alone, we found no
statistical difference in OS between right (68%), left (67%) or rectal located cancers (71%) (HR:
1.17, 95%CI: 0.97–1.43, P = 0.057).
When age of disease onset was considered as a prognostic factor alone, we found that mid-
dle age (40–59 years) and older (60–85 years) patients had a statistically significant higher OS
than younger (20–39 years) patients (69% vs 71% vs 59%, HR: 1.07, 95% CI: 0.91–1.25,
P = 0.008). Additional stratification in patient prognosis profiling could be evidenced when
age of disease onset was considered along with tumor location. When these factors were ana-
lyzed together, we found that left colon located cancers for both middle age (69%) and older
Table 1. Clinicopathological characteristics of patients.
Characteristic Locations (n/%) P value
Right colon (521/23.3) Left colon (740/33.1) Rectum (972/43.5)
Gender 0.164
Male 298 (13.3) 457 (20.5) 561 (25.1)
Female 223 (10.0) 283 (12.7) 411 (18.4)
Age 0.286
20–39 years 52 (2.3) 59 (2.6) 77 (3.4)
40–59 years 243 (10.9) 323 (14.5) 458 (20.5)
60–85 years 226 (10.1) 358 (16.0) 437 (19.6)
Pathology <0.001
G1 40 (1.8) 27 (1.2) 37 (1.7)
G2 426 (19.1) 675 (30.2) 901 (40.3)
G3 5 (0.2) 4 (0.2) 9 (0.4)
Mucinous 45 (2.0) 27 (1.2) 23 (1.0)
Signet-ring 5 (0.2) 7 (0.3) 2 (0.1)
Stage <0.001
I 27 (1.2) 74 (3.3) 230 (10.3)
IIA 195 (8.7) 230 (10.3) 185 (8.3)
IIB 23 (1.0) 36 (1.6) 166 (7.4)
IIC 14 (0.6) 14 (0.6) 14 (0.6)
IIIA 7 (0.3) 16 (0.7) 32 (1.4)
IIIB 119 (5.3) 165 (7.4) 168 (7.5)
IIIC 25 (1.1) 33 (1.5) 34 (1.5)
IVA 63 (2.8) 98 (4.4) 104 (4.7)
IVB 48 (2.1) 74 (3.3) 39 (1.7)
MMR status
dMMR 117 (5.2) 55 (2.5) 60 (2.7) <0.001
pMMR 404 (18.1) 685 (30.7) 912 (40.8)
Alive 0.057
Yes 355 (15.9) 494 (22.1) 695 (31.1)
No 166 (7.4) 246 (11.0) 277 (12.4)
doi:10.1371/journal.pone.0172799.t001
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(67%) patients had a statistically significant higher OS than that for younger (54%) patients
(HR: 0.89, 95%CI: 0.68–1.16, P = 0.048). However this effect was not seen for right colon
located cancers, in this case we found no statistical difference in OS between younger, middle
age or older patients (60% vs 71% vs 67%, HR: 0.84, 95% CI: 0.61–1.16, P = 0.194). An effect
was seen in rectal located cancers when age and tumor location were considered. Here, a statis-
tically significant difference in survival was found for both younger (62%) and middle aged
(68%) patients that had a lower OS than older (77%) patients (HR: 1.46, 95%CI: 1.13–1.88,
P = 0.004).
When dMMR status was considered with location, right colon cancer patients with dMMR
(86%) had higher OS than those patients with pMMR (63%) (HR: 3.01, 95% CI: 1.82–4.97,
P<0.001). Likewise, left colon cancer patients with dMMR (76%) also had higher OS than
those with pMMR (66%) (HR: 1.67, 95% CI: 0.95–2.92, P = 0.01). Oppositely, we found rectal
cancer patients with dMMR (60%) had lower OS than those with pMMR (68%) (HR: 0.77,
95% CI: 0.51–1.17, P = 0.04).
Among the variables analyzed in the multivariate Cox model, stage (HR 3.86, 95%CI: 3.69–
4.01, P = 0.001), pathological differentiation (HR 2.14, 95%CI: 2.07–2.19, P<0.001) and MMR
status (HR 1.23, 95%CI: 1.19–1.26, P<0.001) were significantly associated with tumor location.
However, gender (HR 1.39, 95%CI: 1.35–1.42, P = 0.164) and the age of patients (HR 2.38,
95%CI: 2.33–2.42, P = 0.286) showed no statistical significance with tumor location. The sur-
vival plots of tumor location and age are shown in Fig 2.
Discussion
Colorectal cancer has reported high morbidity and mortality rates worldwide, and according
to the GLOBOCAN report from 2008, an estimated 1.2 million people suffered from CRC,
accounting for approximately 10% of all cancer patients[18].
Various risk factors for CRC have been identified, and these form the basis for screening
recommendations to be provided for patients. CRC, like other types of cancer, demonstrates
an increasing incidence with age. In this current study, middle aged and older classified
patients accounted for 45.9 and 45.7 percent of the CRC patient population studied with youn-
ger patients only accounting for the remaining 8.4% of the CRC cases. This patient distribution
for CRC we found in our study was concordant with the patient breakdown seen in previous
study[19].
The notion that age is a significant prognostic factor in CRC has previously been suggested
but this conclusion has remained somewhat controversial. Previous studies have reported
poorer prognosis among younger patients with CRC[7]. While others have reported that youn-
ger patients with CRC among those surgically treated appeared to have a higher specific sur-
vival rate versus more elderly patients [8,9]. In our report here on Chinese CRC patients, we
found middle and older aged patients had higher OS than younger patients (P = 0.008). Our
observation that cancer related mortality did not decrease with increasing age after those
reaching 50 years old exemplifies the idea that, although elderly patients have a shorter life
expectancy based on their age, still benefited from cancer treatment.
Another factor that we wanted to test that might be useful as a prognostic factor in CRC is
the location of the primary CRC tumor. Different locations within the colon are derived from
different embryonic tissues. The right colon (cecum, ascending colon, and proximal two thirds
of the transverse colon) is derived from the embryonic midgut, whereas the left colon (distal
one third of the transverse colon, descending colon, sigmoid colon, and rectum) is derived
from the embryonic hindgut[20]. It is likely that these different origins of colon tissue could
contribute to CRC disease pathology by independent processes. Indeed, there is already
Combined prognostic effect of location and age in CRC
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evidence to indicate that the clinical characteristics and molecular profiles of gene and protein
expression for CRC differ across these different tissue sites[21,22,23,24]. One previous study
has already shown that the primary tumor location could serve as prognostic factor in meta-
static CRC[25]. Other studies reported about some correlation between patients’ sex and
Fig 2. OS according to the MMR status, tumor location and age.
doi:10.1371/journal.pone.0172799.g002
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tumor location [26,27]. However, in this study we found no statistical association between sex
and tumor location. In this study, we found no statistical difference in OS between right can-
cer, left cancer and rectal cancer (P = 0.057). It is not yet clear why we did not find a similar
result when analyzing tumor location alone independent of age of disease onset. Yet, when
tumor location was considered along with age of onset, we could find statistically significant
associations for tumor location to disease survival.
Tumor location and age of onset are two basic clinical characteristics of CRC. To date, only
a limited number of prospective studies have evaluated the relation between tumor location
and age of onset to the prognosis of CRC. It has been previously reported that right-sided
early-onset colon cancers were a subset in which most Lynch Syndrome cases could be found,
with earlier stages of disease at diagnosis having better prognosis[16]. In another study, the
Bax/Bcl-2 ratio was statistically correlated for CRC against age and tumor location. Here,
patients older than 50 showed decreased levels of Bax/Bcl-2 ratio. Moreover, with regard to
tumor location, the Bax/Bcl-2 ratio was found to be significantly lower in colon compared to
rectal cancer[17]. However, one potential caveat to these findings is that both studies only
focused on a select age group of cancer patients.
In our current study, we found two possibly important associations for tumor location and
age of disease onset to OS of CRC patients. First in left colon located cancers, middle (69%)
and older aged (67%) patients were found to have higher OS than younger (54%) patients
(P = 0.048). Second in rectal located cancers, we found the younger (62%) and middle aged
(68) patients had lower OS than older (77%) patients (P = 0.004). According to the well-
accepted model of CRC progression by Vogelstein, malignancy arises with aging as a result of
accumulation of mutations in tumor suppressor genes and oncogenes [28,29]. Because we
have noticed differences in OS with regard to tumor location and not necessarily due to age,
our results suggest that another factor in disease could be from accumulation effect of muta-
tions that differ in various tissue locations. Recently, it was reported that human intestinal
microbiota and bacterial metabolites contributed to the aetiology of CRC[30]. It is likely that
possible mechanisms are involved and gaining understanding of these processes will aid in the
prognosis of CRC patients.
From our analysis we were able to find that more frequent occurrences of mucinous, high-
grade and signet-ring phenotype in right colon cancers (9.6%) compared with left colon cancer
(4.6%) and rectal cancer (2.6%). It is of note that right lesions have more frequently been
reported to be related to dMMR status tumors. One explanation for this finding is that the
right and left colon arise from different embryological sources [31].
In clinical practice, the tumor’s MMR status is increasingly being used to guide clinical
management. Stage II patients with dMMR have a better prognosis and may actually be
harmed by 5-FU treatment[32]. We found that patients with right tumors had no prognostic
difference compared with patients who had left colon and rectal tumors, which contradicted to
the previous findings of others[33,34]. Yet in our current study, we did find that dMMR status
could show benefit as a prognostic biomarker for right and left colon cancer. As well, dMMR
gave indications for bad prognosis of rectal cancers. Overall we found that the separate evalua-
tion of tumor location appears to have some predictive and prognostic value when combined
with MMR status for colon and rectal cancers.
Conclusions
We have found that the combination of age and tumor location can be a significant predictor
of overall survival in CRC. This finding solidifies the notion that despite the morbidity and
mortality associated with any CRC diagnosis, baseline patient characteristics might still
Combined prognostic effect of location and age in CRC
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provide predictive information as to a given patient’s outcome and also can help the clinician
to predict the clinical course and response of chemotherapy. Our findings also confirm the
importance of location of primary tumor and indicate that tumors resected from different
locations of the colorectum have different dMMR status that can work as prognostic biomark-
ers in colorectal cancer.
The increasing trend in the CRC mortality indicate that improved primary and secondary
prevention measures are particularly still needed and could be further aided by better prognos-
tic methods being made available.
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In our large data, we accessed 2,233 colorectal cancer patients to analyze the Ki67 expression, MMR 
status, age of onset and tumor locations regarding overall survival of the CRCs. In the first part, we 
focused on the possibility of Ki67 as a prognostic biomarker for CRC. Our study has shown that stage III 
CRC patients with a high Ki67 expression had an improved overall survival compared to patients with a 
low Ki67 expression. However, for stage I and II CRCs we found no statistical difference between 
patients with high Ki67-Li and patients with low Ki67-Li. Remarkably, it is shown that stage IV CRC 
patients with low Ki67-Li had improved progression free survival (PFS). However, this benefit was not 
found in the overall survival (OS) for the same stage patients. In previous studies, the prognostic effect 
of Ki67-Li was shown in breast cancer and renal cell cancer. Our study provided further large-data 
evidence for Ki67 expression as a biomarker for CRCs management.  
 
In the second part, we analyzed the association between age of tumor onset and MMR status in 
regard to CRC prognosis. In general, young patients had a decreased OS rate compared with middle-
age and elderly patients. When stratified by MMR status, the young patients with dMMR status had 
better OS than young patients with pMMR status. The situation was similar for middle-age patients. 
However, the prognostic impact of MMR showed no statistical difference for elderly patients. This 
result demonstrated that the prognostic influence of MMR status may shift during different ages of 
disease onset. 
 
In the third part, we analyze the relationship of age and tumor location and the association between 
MMR status and tumor location. In general, young patients with CRC had the worst prognosis 
compared with middle-age and elderly patients. However, the elderly rectal cancer patients had better 
prognosis compared with young and middle-age patients. When MMR status was considered, the 
colon cancer patients with dMMR had better prognosis than the patients with pMMR. However, 
concerning rectal cancer patients, the patients with pMMR had better prognosis than the patients 
with dMMR. 
 
At present, the treatment of CRC is in a period of stagnation. More research is required combining the 








In unseren großen Datenbank haben wir auf 2.233 Patienten mit Kolorektalkarzinomen zugegriffen, 
um die Ki67-Expression, den MMR-Status, das Alter bei Krankheitsbeginn und die Tumorlokalisation in 
Bezug auf das Gesamtüberleben der CRCs zu analysieren. Im ersten Teil untersuchten wir die 
Möglichkeit von Ki67 als prognostischen Biomarker für CRC. Unsere Studie hat ergeben, dass Stadium 
III CRC Patienten mit einer hohen Ki67-Expression ein verbessertes Gesamtüberleben im Vergleich zu 
Patienten mit einer niedrigen Ki67-Expression hatten. Allerdings fanden wir für die Stadium I und II 
CRCs keinen statistischen Unterschied zwischen Patienten mit hohem Ki67-Li und Patienten mit 
niedrigem Ki67-Li. Überraschenderweise zeigte sich, dass Stadium IV CRC Patienten mit niedrigem 
Ki67-Li ein verbessertes progressionsfreies Überleben (PFS) hatten. Allerdings wurde dieser Benefit 
nicht im Gesamtüberleben (OS) für die Patienten im gleichen Stadium gefunden. In früheren Studien 
wurde die prognostische Wirkung von Ki67-Li bei Brustkarzinomen und Nierenzellkarzinomen gezeigt. 
Unsere Studie lieferte weitere Beisweise aus einer großen Datenbank für Ki67 als Biomarker für CRCs 
Management. 
 
Im zweiten Teil analysierten wir den Zusammenhang zwischen dem Alter bei Krankheitsbeginn und 
dem MMR-Status in Bezug auf die CRC-Prognose. Im Allgemeinen hatten junge Patienten eine 
verminderte OS-Rate im Vergleich zu Patienten mittleren Alters und älteren Patienten. Wenn sie durch 
den MMR-Status geschichtet wurden, hatten die jungen Patienten mit dMMR-Status eine bessere 
Prognose als junge Patienten mit pMMR-Status. Die Situation war ähnlich für Patienten mittleren 
Alters. Allerdings zeigte die prognostische Wirkung von MMR keinen statistischen Unterschied bei 
älteren Patienten. Dieses Ergebnis zeigte, dass sich der prognostische Einfluss des MMR-Status je nach 
Alter bei Ausbruch der Erkrankung verschieben kann. 
 
Im dritten Teil analysieren wir das Verhältnis von Alter und Tumorlokalisation und den Zusammenhang 
zwischen MMR-Status und Tumorlokalisation. Im Allgemeinen hatten junge Patienten mit CRC eine 
schlechte Prognose im Vergleich zu Patienten mittleren Alters und älteren Patienten. Allerdings hatten 
die älteren Patienten mit Rektalkarzinomen bessere Prognose im Vergleich zu jungen und Patienten 
mittleren Alters. Als der MMR-Status in Betracht gezogen wurde, hatten bei den Patienten mit 
Kolonkarzinomen diejenigen mit dMMR eine bessere Prognose als diejenigen mit pMMR. Bei den 
rektalen Krebspatienten hatten diejenigen mit pMMR jedoch eine bessere Prognose als diejenigen mit 
dMMR. 
 
Gegenwärtig befindet sich die Behandlung von CRC in einer Zeit der Stagnation. Wir müssen mehr 
Forschungen machen, die die klinischen Faktoren und biologischen Mechanismen kombinieren, um 
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